These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9155708)

  • 1. The pathology of the ring-substituted amphetamine analogue 3,4-methylenedioxymethylamphetamine (MDMA, 'Ecstasy').
    Rutty GN; Milroy CM
    J Pathol; 1997 Mar; 181(3):255-6. PubMed ID: 9155708
    [No Abstract]   [Full Text] [Related]  

  • 2. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage?
    Gouzoulis-Mayfrank E; Daumann J
    Addiction; 2006 Mar; 101(3):348-61. PubMed ID: 16499508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Brain functional disorders after taking Ecstasy?].
    von Wilmsdorff M; Gastpar M
    Dtsch Med Wochenschr; 1995 Dec; 120(49):1716. PubMed ID: 7497899
    [No Abstract]   [Full Text] [Related]  

  • 4. Hazards associated with the recreational drug 'ecstasy'.
    O'Connor B
    Br J Hosp Med; 1994 Nov 16-Dec 13; 52(10):507, 510-4. PubMed ID: 7858800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [3,4-methylenedioxymethamphetamine ('ecstasy'): its long-term emotional and cognitive effects, and serotonin depletion].
    Molero-Chamizo A
    Rev Neurol; 2005 Jul 16-31; 41(2):108-14. PubMed ID: 16028190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDMA, methamphetamine and their combination: possible lessons for party drug users from recent preclinical research.
    Clemens KJ; McGregor IS; Hunt GE; Cornish JL
    Drug Alcohol Rev; 2007 Jan; 26(1):9-15. PubMed ID: 17364831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preexposure to MDMA ("Ecstasy") delays acquisition but facilitates MDMA-induced reinstatement of amphetamine self-administration behavior in rats.
    Morley KC; Cornish JL; Li KM; McGregor IS
    Pharmacol Biochem Behav; 2004 Oct; 79(2):331-42. PubMed ID: 15501310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Qualitative review of serotonin syndrome, ecstasy (MDMA) and the use of other serotonergic substances: hierarchy of risk.
    Silins E; Copeland J; Dillon P
    Aust N Z J Psychiatry; 2007 Aug; 41(8):649-55. PubMed ID: 17620161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects and risks of substituted amphetamines (Ecstasy)].
    Huether G
    Internist (Berl); 1998 Mar; 39(3):312-3. PubMed ID: 9561453
    [No Abstract]   [Full Text] [Related]  

  • 10. Memory performance in polyvalent MDMA (ecstasy) users who continue or discontinue MDMA use.
    Gouzoulis-Mayfrank E; Fischermann T; Rezk M; Thimm B; Hensen G; Daumann J
    Drug Alcohol Depend; 2005 Jun; 78(3):317-23. PubMed ID: 15893163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of Impulsivity and Serotonin Receptor Neuroadaptations to the Development of an MDMA ('Ecstasy') Substance Use Disorder.
    Schenk S; Aronsen D
    Curr Top Behav Neurosci; 2017; 34():17-32. PubMed ID: 26718587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bruxism after 3,4-methylenedioxymethamphetamine (ecstasy) abuse.
    Dinis-Oliveira RJ; Caldas I; Carvalho F; Magalhães T
    Clin Toxicol (Phila); 2010 Oct; 48(8):863-4. PubMed ID: 20515398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recreational use of 3,4-methylenedioxymethamphetamine ('ecstasy') relieving symptoms of posterior scleritis.
    Witters JG; Kestelyn P; Van Slycken S; Verstraete A; Van Aken EH
    Eye (Lond); 2007 Dec; 21(12):1535-7. PubMed ID: 17891054
    [No Abstract]   [Full Text] [Related]  

  • 14. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
    Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A
    J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy.
    Parrott AC
    J Psychopharmacol; 2005 Jan; 19(1):71-83. PubMed ID: 15671132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ecstasy in the brain: a model for neuroimaging.
    Hurley RA; Reneman L; Taber KH
    J Neuropsychiatry Clin Neurosci; 2002; 14(2):125-9. PubMed ID: 11983786
    [No Abstract]   [Full Text] [Related]  

  • 17. The agony of the ecstasy: serotonin and obstructive sleep apnea.
    Chamberlin NL; Saper CB
    Neurology; 2009 Dec; 73(23):1947-8. PubMed ID: 19955498
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacological aspects of the combined use of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and gamma-hydroxybutyric acid (GHB): a review of the literature.
    Uys JD; Niesink RJ
    Drug Alcohol Rev; 2005 Jul; 24(4):359-68. PubMed ID: 16234132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive deficits and cognitive normality in recreational cannabis and Ecstasy/MDMA users.
    Parrott A
    Hum Psychopharmacol; 2003 Mar; 18(2):89-90. PubMed ID: 12590401
    [No Abstract]   [Full Text] [Related]  

  • 20. MDMA and serotonin: based on two cases.
    Garcia Cabeza I; Zabala A; Soto-Montenegro ML; Arango C
    Actas Esp Psiquiatr; 2005; 33(5):339-42. PubMed ID: 16155817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.